Beyond the cardiac myofilament: Hypertrophic cardiomyopathy-associated mutations in genes that encode calcium-handling proteins

Current Molecular Medicine

Volumn 12, Issue 5, 2012, Pages 507-518

  Landstrom, A P ^a   Ackerman, M J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Calcium; genetics; hypertrophic cardiomyopathy; junctophilin; mutation; phospholamban; troponin

Indexed keywords

CALRETICULIN; CALSEQUESTRIN; PHOSPHOLAMBAN; RYANODINE RECEPTOR 2; SORCIN; TROPONIN C;

ARTICLE; CALCIUM SIGNALING; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOFILAMENT; SARCOMERE; STRUCTURE ACTIVITY RELATION;

EID: 84860991214     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800620020     Document Type: Article

References (109)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20: 1-8.
2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995; 92: 785-789.
3. Maron B, Roberts W, McAllister H, Rosing D, Epstein S. Sudden death in young athletes. Circulation 1980; 62: 218-229.
4. Maron B, Epstein S, Roberts W. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7: 204-214.
5. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol 2007; 22: 193-199.
6. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075.
7. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002; 287: 1308-1320.
8. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104: 2517-2524.
9. McKenna WJ, Borggrefe M, England D, Deanfield J, Oakley CM, Goodwin JF. The natural history of left ventricular hypertrophy in hypertrophic cardiomyopathy: an electrocardiographic study. Circulation 1982; 66: 1233-1240.
10. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 123-129.
11. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989; 321: 1372-1378.
12. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62: 999-1006.
13. Morner S, Richard P, Kazzam E, et al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. J Mol Cell Cardiol 2003; 35: 841-849.
14. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet 2003; 64: 339-349.
15. van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80: 739-744.
16. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107: 2227-2232.
17. van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc 2005; 80: 463-469.
18. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996; 13: 63-69.
19. Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation 2002; 105: 2337-2340.
20. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11: 434-437.
21. Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103: R39-R43.
22. Thierfelder L, Watkins H, MacRae C, et al. Alphatropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77: 701-712.
23. Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997; 16: 3793-82.
24. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: Identification of a novel disease gene. Biochem Biophys Res Comm 1999; 262: 411-417.
25. Arimura T, Bos JM, Sato A, et al. Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 334-342.
26. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation 2010; 122: 2441-2450.
27. van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation 2003; 108: 445-451.
28. van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44: 1903-1910.
29. Binder J, Ommen SR, Gersh BJ, et al. Echocardiographyguided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006; 81: 459-467.
30. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Geßner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum Mutat 2001; 17: 524.
31. Schmidtmann A, Lindow C, Villard S, et al. Cardiac troponin C-L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C. FEBS Journal 2005; 272: 6087-6097.
32. Baryshnikova OK, Li MX, Sykes BD. Modulation of cardiac troponin C function by the cardiac-specific N-terminus of troponin I: Influence of PKA phosphorylation and involvement in cardiomyopathies. J Mol Biol 2008; 375: 735-751.
33. Liang B, Chung F, Qu Y, et al. Familial hypertrophic cardiomyopathy-related cardiac troponin C mutation L29Q affects Ca2+ binding and myofilament contractility. Physiol Genomics 2008; 33: 257-266.
34. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev 2000; 80: 853-924.
35. Landstrom AP, Parvatiyar MS, Pinto JR, et al. Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol 2008; 45: 281-288.
36. Lim CC, Yang H, Yang M, et al. A novel mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity and cardiomyocyte contractility. Biophys J 2008; 94: 3577-3589.
37. Dyer EC, Jacques AM, Hoskins AC, et al. Functional analysis of a unique troponin C mutation, GLY159ASP, that causes familial dilated cardiomyopathy, studied in explanted heart muscle. Circ Heart Fail 2009; 2: 456-464.
38. Gomes AV, Potter JD. Molecular and cellular aspects of troponin cardiomyopathies. Ann NY Acad Sci 2004; 1015: 214-224.
39. Willott RH, Gomes AV, Chang AN, Parvatiyar MS, Pinto JR, Potter JD. Mutations in Troponin that cause HCM, DCM AND RCM: What can we learn about thin filament function? J Mol Cell Cardiol 2010; 48: 882-892.
40. Pinto JR, Parvatiyar MS, Jones MA, Liang J, Ackerman MJ, Potter JD. A functional and structural study of troponin C mutations related to hypertrophic cardiomyopathy. J Biol Chem 2009; 284: 19090-19100.
41. Swindle N, Tikunova SB. Hypertrophic cardiomyopathylinked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C. Biochemistry 2010; 49: 4813-4820.
42. Chung W, Kitner C, Maron B. Novel frameshift mutation in troponin C (TNNC1) associated with hypertrophic cardiomyopathy and sudden death. Cardiol Young 2011; 21 93: 345-348.
43. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 201-211.
44. Bers D. Excitation-Contraction Coupling and Cardiac Contractile Force. Boston: Kluwer Academic Publisher; 2001.
45. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
46. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol Cell Physiol 1983; 245: C1-C14.
47. Wang S-Q, Song L-S, Lakatta EG, Cheng H. Ca2+ signaling between single L-type Ca2+ channels and ryanodine receptors in heart cells. Nature 2001; 410: 592-596.
48. Stern MD, Song L-S, Cheng H, et al. Local control models of cardiac excitation-contraction coupling. J Gen Physiol 1999; 113: 469-489.
49. Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J Biol Chem 1986; 261: 1333341.
50. Inui M, Chamberlain BK, Saito A, Fleischer S. The nature of the modulation of Ca2+ transport as studied by reconstitution of cardiac sarcoplasmic reticulum. J Biol Chem 1986; 261: 1794-1800.
51. Landstrom A, Adekola B, Bos J, Ommen S, Ackerman M. PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: Summary of the literature and implications for genetic testing. Am Heart J 2011; 161: 165-171.
52. Minamisawa S, Sato Y, Tatsuguchi Y, et al. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem. Biophys Res Commun 2003; 304: 1-4.
53. Medin M, Hermida-Prieto M, Monserrat L, et al. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN - 42 C>G mutation. Eur J Heart Fail 2007; 9: 37-43.
54. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 111: 869-876.
55. Chiu C, Tebo M, Ingles J, et al. Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2007; 43: 337-343.
56. Weisleder N, Takeshima H, Ma J. Immuno-proteomic approach to excitation-contraction coupling in skeletal and cardiac muscle: Molecular insights revealed by the mitsugumins. Cell Calcium 2008; 43: 1-8.
57. Garbino A, van Oort RJ, Dixit SS, Landstrom AP, Ackerman MJ, Wehrens XHT. Molecular evolution of the junctophilin gene family. Physiol Genomics 2009; 37: 175-186.
58. Nishi M, Mizushima A, Nakagawara K, Takeshima H. Characterization of human junctophilin subtype genes. Biochem. Biophys Res Commun 2000; 273: 920-927.
59. Takeshima H, Komazaki S, Nishi M, Iino M, Kangawa K. Junctophilins: a novel family of junctional membrane complex proteins. Mol Cell 2000; 6: 11-22.
60. Ziman AP, Gómez-Viquez NL, Bloch RJ, Lederer WJ. Excitation-contraction coupling changes during postnatal cardiac development. J Mol Cell Cardiol 2010; 48: 379-386.
61. Minamisawa S, Oshikawa J, Takeshima H, et al. Junctophilin type 2 is associated with caveolin-3 and is down-regulated in the hypertrophic and dilated cardiomyopathies. Biochem Biophys Res Commun. 2004; 325:852-856.
62. Xu M, Zhou P, Xu S-M, et al. Intermolecular failure of L-type Ca2 channel and ryanodine receptor signaling in hypertrophy. PLoS Biology 2007; 5: e21.
63. Wei S, Guo A, Chen B, et al. T-tubule remodeling during transition from hypertrophy to heart failure. Circ Res 2010; 107: 520-531.
64. Landstrom A, Kellen C, Dixit S, et al. Junctophilin-2 expression silencing causes cardiocyte hypertrophy and abnormal intracellular calcium-handling. Circ Heart Fail. 2011; 4(2): 214-223.
65. van Oort RJ, Garbino A, Wang W, et al. Disrupted junctional membrane complexes and hyperactive ryanodine receptors after acute junctophilin knockdown in mice / clinical perspective. Circulation 2011; 123: 979-988.
66. Landstrom AP, Weisleder N, Batalden KB, et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol. 2007; 42: 1026-1035.
67. Woo JS, Kim DH, Allen PD, Lee EH. TRPC3-interacting triadic proteins in skeletal muscle. Biochem J 2008; 411: 399-405.
68. Woo J, Hwang J, Ko J, Kim D, Ma J, Lee E. Glutamate at position 227 of junctophilin-2 is involved in binding to TRPC3. Mol Cell Biochem 2009; 328(1-2): 25-32.
69. Lee EH, Cherednichenko G, Pessah IN, Allen PD. Functional coupling between TRPC3 and RyR1 regulates the expressions of key triadic proteins. J Biol Chem 2006; 281: 10042-10048.
70. Woo JS, Hwang JH, Ko JK, et al. S165F mutation of junctophilin 2 affects Ca2+ signalling in skeletal muscle. Biochem J 2010; 427: 125-134.
71. Matsushita Y, Furukawa T, Kasanuki H, et al. Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy. J Hum Genet 2007; 52: 543-548.
72. Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001; 103(4): 485-490.
73. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200.
74. Tester DJ, Dura M, Carturan E, et al. A mechanism for sudden infant death syndrome (SIDS): Stress-induced leak via ryanodine receptors. Heart Rhythm 2007; 4: 733-739.
75. Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10: 189-194.
76. Fujino N, Ino H, Hayashi K, et al. Abstract 915: A novel missense mutation in cardiac ryanodine receptor gene as a possible cause of hypertrophic cardiomyopathy: Evidence from familial analysis. Circulation 2006; 114: 2, 165.
77. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either ctecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: A comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009; 54: 2065-2074.
78. Chiu C, Bagnall RD, Ingles J, et al. Mutations in alphaactinin-2 cause hypertrophic cardiomyopathy: A genomewide analysis. J Am Coll Cardiol 2010; 55: 1127-1135.
79. Marx SO, Reiken S, Hisamatsu Y, et al. Phosphorylationdependent regulation of ryanodine receptors. J Cell Biol 2001; 153: 699-708.
80. Valdivia HH, Kaplan JH, Ellis-Davies GC, Lederer WJ. Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation. Science 1995; 267: 1997-2000.
81. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000; 101: 365-376.
82. Bers DM, Eisner DA, Valdivia HH. Sarcoplasmic reticulum Ca2+ and heart failure: Roles of diastolic leak and Ca2+ transport. Circ Res 2003; 93: 487-490.
83. Kaftan E, Marks AR, Ehrlich BE. Effects of rapamycin on ryanodine receptor/Ca2+-release channels from cardiac muscle. Circ Res 1996; 78: 990-997.
84. Wehrens XHT, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 2004; 94: e61-e70.
85. Franzini-Armstrong C, Kenney LJ, Varriano-Marston E. The structure of calsequestrin in triads of vertebrate skeletal muscle: a deep-etch study. J Cell Biol 1987; 105: 49-56.
86. Jones LR, Suzuki YJ, Wang W, et al. Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J Clin Invest 1998; 101: 1385-1393.
87. Sato Y, Ferguson DG, Sako H, et al. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 1998; 273: 28470-28477.
88. Postma AV, Denjoy I, Hoorntje TM, et al. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2002; 91: e21-e26.
89. di Barletta MR, Viatchenko-Karpinski S, Nori A, et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 2006; 114: 1012-1019.
90. Nakamura K, Zuppini A, Arnaudeau S, et al. Functional specialization of calreticulin domains. J. Cell Biol. 2001; 154: 961-972.
91. Meyers MB, Zamparelli C, Verzili D, Dicker AP, Blanck TJJ, Chiancone E. Calcium-dependent translocation of sorcin to membranes: functional relevance in contractile tissue. FEBS Lett 1995; 357: 230-234.
92. Farrell E, Antaramian A, Rueda A, Gomez A, Valdivia H. Sorcin inhibits calcium release and modulates excitationcontraction coupling in the heart. J Biol Chem 2003; 278: 34660-34666.
93. Meyers M, Puri T, Chien A, et al. Sorcin associates with the pore-forming subunit of voltage-dependent L-type Ca2+ channels. J Biol Chem 1998; 30: 18930-18935.
94. Lokuta A, Meyers M, Sander P, Fishman G, Valdivia H. Modulation of cardiac ryanodine receptors by sorcin. J Biol Chem 1997; 272: 25333-25338.
95. Mohiddin S, Antaramian A, Farrell E, et al. Abstract - A naturally-occurring sorcin missense mutation (F112L) is associated with hypertrophic cardiomyopathy, hypertension, and impaired modulation of cardiac ryanodine receptor. Circulation 2002; 106: 2, 319.
96. Buetow KH, Edmonson MN, Cassidy AB. Reliable identification of large numbers of candidate SNPs from public EST data. Nat Genet 1999; 21: 323-325.
97. Brookes AJ, Lehvaslaiho H, Siegfried M, et al. HGBASE: a database of SNPs and other variations in and around human genes. Nucl Acids Res 2000; 28: 356-360.
98. Collis LP, Meyers MB, Zhang J, et al. Expression of a sorcin missense mutation in the heart modulates excitationcontraction coupling. FASEB J 2007; 21: 475-487.
99. Valdivia H, Farrell E, Antaramian A, et al. Sorcin and ryanodine receptors in heart failure. J Muscle Res Cell Motil 2004; 25: 605-607.
100. Franceschini S, Ilari A, Verzili D, et al. Molecular basis for the impaired function of the natural F112L sorcin mutant: X-ray crystal structure, calcium affinity, and interaction with annexin VII and the ryanodine receptor. FASEB J 2008; 22: 295-306.
101. Maier LS, Bers DM. Calcium, calmodulin, and calciumcalmodulin kinase II: heartbeat to heartbeat and beyond. J Mol Cell Cardiol 2002; 34: 919-939.
102. Zhang T, Brown JH. Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 2004; 63: 476-486.
103. Houser S, Molkentin J. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci Signal 2008; 1: pe31.
104. Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000; 105: 1395-1406.
105. Little GH, Bai Y, Williams T, Poizat C. Nuclear calcium/calmodulin-dependent protein kinase II{delta} preferentially transmits signals to histone deacetylase 4 in cardiac cells. J Biol Chem 2007; 282: 7219-7231.
106. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110: 479-488.
107. Molkentin JD, Lu J-R, Antos CL, et al. A calcineurindependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
108. Bourajjaj M, Armand A-S, da Costa Martins PA, et al. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008; 283: 22295-22303.
109. Landstrom AP, Ackerman MJ. GWAS or Gee Whiz, PSAS or Pshaw: Elucidating the biologic and clinical significance of genetic variation in cardiovascular disease. Heart Rhythm 2009; 6: 1751-1753.